BMS-214662 in Treating Patients With Solid Tumors

Phase I Study of Farnesyl Transferase Inhibitor BMS-214662 (NSC 710086D) in Solid Tumors

Phase I trial to study the effectiveness of BMS-214662 in treating patients who have solid tumors. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die

Study Overview

• Status: Completed
• Conditions: Unspecified Childhood Solid Tumor, Protocol Specific; Unspecified Adult Solid Tumor, Protocol Specific
• Intervention / Treatment: Other: laboratory biomarker analysis; Drug: BMS-214662

Detailed Description

OBJECTIVES:

I. Determine the maximum tolerated dose of BMS-214662 in patients with solid tumors.

II. Evaluate intermediate biological endpoints as surrogates for the effectiveness of this drug in these patients.

III. Determine the nature of dose limiting toxicity of this drug in this patient population.

IV. Determine the recommended phase II regimen of this drug in these patients. V. Establish a pharmacologic and pharmacokinetic profile of this drug in these patients.

OUTLINE: This is a dose escalation study.

Patients receive BMS-214662 IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of BMS-214662 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients experience dose limiting toxicities.

Patients are followed every 3 months for at least 24 months.

• Study Type: Interventional
• Enrollment (Actual): 36
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • Texas
    • Houston, Texas, United States, 77030
      • M D Anderson Cancer Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Diagnosis of malignant solid tumor for which a standard curative therapy does not exist
• Performance status - Karnofsky 70-100%
• At least 6 months
• WBC at least 3,000/mm^3
• Absolute neutrophil count at least 1,500/mm^3
• Platelet count at least 100,000/mm^3
• Hemoglobin at least 10.0 g/dL
• Bilirubin no greater than 2.0 mg/dL
• AST no greater than 2 times upper limit of normal
• Albumin at least 3.0 g/dL
• Creatinine no greater than 1.5 mg/dL
• No uncontrolled heart disease
• No history of clinically significant cardiac arrhythmia that could be exacerbated by QT interval prolongation
• Corrected QT interval no greater than 450 milliseconds
• Must not require total parenteral nutrition
• No manifestations of malabsorption syndrome due to prior surgery, gastrointestinal disease, or unknown reasons
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No signs or symptoms of acute infection requiring systemic therapy
• No grade 3 or 4 neurotoxicity from prior anticancer treatment or neuropathy from any cause
• No confusion, disorientation, or psychiatric illness that may preclude study
• No more than 3 prior chemotherapy regimens
• At least 4 weeks since prior chemotherapy (6 weeks since prior nitrosoureas or mitomycin) and recovered
• No other concurrent antineoplastic agents
• No concurrent hormonal anticancer therapy
• At least 4 weeks since prior radiotherapy
• No concurrent radiotherapy
• Prior drugs known to prolong the QT interval allowed if they can be safely discontinued for a time period equal to 4 elimination half-lives prior to administering study drug
• No drugs known to prolong the QT interval during and for 24 hours after study drug
• No concurrent therapy with known CYP3A4 substrates
• No other concurrent investigational agents

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Treatment; Patients receive BMS-214662 IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.	Other: laboratory biomarker analysis; Correlative studies; Drug: BMS-214662; Given IV; Other Names: farnesyltransferase inhibitor BMS-214662; FTI BMS 214662

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
MTD, defined as the dose level among the 9 levels studied having toxicity rate closest to a target of 33%, graded according to CTC version 2.0	Toxicity is defined as grade 3, 4 non-hematologic and grade 4 hematologic (neutropenia and thrombocytopenia) toxicity. The continual reassessment method (CRM) will be used.	Up to 6 weeks

Collaborators and Investigators

• Sponsor: National Cancer Institute (NCI)
• Investigators: Principal Investigator: Vassiliki Papadimitrakopoulou, M.D. Anderson Cancer Center

Study record dates

Study Major Dates

• Study Start: April 1, 2000
• Primary Completion (Actual): July 1, 2004

Study Registration Dates

• First Submitted: July 5, 2000
• First Submitted That Met QC Criteria: January 26, 2003
• First Posted (Estimate): January 27, 2003

Study Record Updates

• Last Update Posted (Estimate): January 23, 2013
• Last Update Submitted That Met QC Criteria: January 22, 2013
• Last Verified: January 1, 2013

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms
• Other Study ID Numbers: NCI-2012-02343; U01CA062461 (U.S. NIH Grant/Contract); ID99-304; CDR0000067960 (Registry Identifier: PDQ (Physician Data Query))